Esperion Therapeutics, Inc. to Host Conference Call on September 3, 2013 to Announce Top-line Results from a Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia

Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host a conference call and webcast on Tuesday, September 3, 2013 at 8:30 a.m. Eastern Time (ET) to present top-line results from a Phase 2a clinical study of its lead product candidate, ETC-1002, as an add-on to statin therapy in patients with hypercholesterolemia.

Help employers find you! Check out all the jobs and post your resume.